Joseph Catanzaro, PhD

Joe Catanzaro is a director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in 2018, Catanzaro spent four years at Cowen, where he also covered biotechnology. Before making the move to Wall Street, Catanzaro worked as a research scientist at Stony Brook University in New York. His work there focused on oncogene-mediated inflammatory signaling and resulted in multiple peer-reviewed publications. Catanzaro received his bachelor’s degree from Binghamton University in biological sciences and earned his Ph.D. in genetics from Stony Brook University.

Universe Coverage

Biotechnology
CTMX	CytomX Therapeutics, Inc.
CPRX	Catalyst Pharmaceuticals, Inc.
CRDF	Cardiff Oncology, Inc.
RPTX	Repare Therapeutics Inc.
HALO	Halozyme Therapeutics, Inc.
IOVA	Iovance Biotherapeutics, Inc.
SGEN	Seagen, Inc.
KROS	Keros Therapeutics, Inc.
IMGN	ImmunoGen, Inc.
OCUL	Ocular Therapeutix, Inc.
IMAB	I-Mab
EPIX	ESSA Pharma, Inc.
ACHL	Achilles Therapeutics, Inc.
GRCL	Gracell Biotechnologies Inc.
NRIX	Nurix Therapeutics, Inc.
BMEA	Biomea Fusion, Inc.
LPTX	Leap Therapeutics, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
AADI	Aadi Bioscience, Inc.
IBRX	ImmunityBio, Inc.
ACRV	Acrivon Therapeutics, Inc.
RAIN	Rain Oncology, Inc.
GILD	Gilead Sciences, Inc.
SDGR	Schrodinger, Inc.
EXEL	Exelixis, Inc.
BDTX	Black Diamond Therapeutics, Inc.
MRTX	Mirati Therapeutics, Inc.
TSBX	Turnstone Biologics Corp.